Denise Strauss, formerly VP of cardiovascular marketing at Boehringer Ingelheim, will oversee the drugmaker's marketing activities.
Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.
The chief creative officer at Carling Communications talks about how she learned that the best leaders are only as good as the performance of their team.
The company hired Christine Cassiano, who is charged with preparing the communications strategy for the drugmaker's experimental cancer therapy.
The company promoted Maryellen Royle to global CEO of Tonic Life Communications and Jon Clark to global CEO of Nitrogen.
Roberts reports to Ken Begasse, founder and CEO of Concentric Health Experience.
J&J insulin pumps are at risk of hacking; Merrimack CEO leaves and cuts workforce; Japanese scientists wins Nobel
Physicians are seeking beyond-the-pill services from drugmakers; Novartis debunks misconception that only smokers get lung cancer; pharma's access to docs declines
A new report analyzing gender parity in advertising found that men tend to endorse other men at higher rates than women. Execs share their insights about the issue.
WebMD said David Schlanger left the company under mutual agreement, and that Steven Zatz replaced him as CEO.
The vice president of audience development talks about her days in the dot-com world and how struggling in a new role shaped her career.
They share their insights, secrets, worries, and everything else in between.
The new SVP and GM of health believes that the Dentsu Aegis deal would provide scale and efficiencies.
Hint: it pays to be an EVP.
Execs say that career prospects are better than ever. Yet data from MM&M's annual Career and Salary Survey reveals a decline in growth.
When the Career and Salary Survey made its debut, in 1987, Eli Lilly's Prozac led the list of mass-market drug launches and AIDS therapy had taken a big step forward with the approval of GlaxoSmithKline's AZT, a year earlier.
"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."
Retzlaff files a complaint against Turing; Pfizer to buy antibiotics from AstraZeneca; Mylan's marketing for EpiPen faces criticism
The current reimbursement climate is more likely to impact how drugmakers order their global product launches than the U.K.'s vote to exit the E.U.
Only one new osteoporosis drug has been approved over the last six years.
Valeant reorganizes executive team; experimental asthma drug developed by Novartis shows promising results; Teva launches generic Gleevec
The popular fitness tracker maker hired Adam Pellegrini, Walgreens' VP of digital health, to boost pharma and healthcare deals.
MM&M's 2016 Hall of Femme honorees talk about who inspires them, describe their "Raphael moments," and share their experiences as women leaders.
Here's everything you missed or may want to revisit from MM&M's inaugural Hall of Femme event in June.
A story about a boss giving away a woman's bonus to a man based on his breadwinning status resonated with Hall of Femme attendees.
The reaction from social media was swift and brutal, with figures from all levels of the advertising industry blasting Roberts for his comments.
Until now, your superiors have promoted you. Now it's your responsibility to show why you belong.
She will be responsible for the medical device practice's strategy and operations across all W2O Group agencies.
Avanir's success with Nuedexta sparked the attention of several suitors. In 2014 the company reached a deal to be sold to Otsuka Pharmaceutical for around $3.5 billion
Twenty shops, including Co:Collective, Wolff Olins, and 72andSunny, have signed onto the Pledge Parental Leave coalition since March.
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Tuesday, October 18, 2016
- Five things for pharma marketers to know: Wednesday, October 19, 2016
- FCB Health's Rich Levy on HIV/AIDS Campaigns that Fight Stigma
- Five things for pharma marketers to know: Monday, October 24, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy